Market News & Trends
Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine
Silo Pharma, Inc. recently announced its planned attendance at a hybrid public meeting on June 27, 2024, hosted by the US FDA in partnership with…
AbbVie & Gilgamesh Pharmaceuticals Announce Collaboration & Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders
Collaboration to leverage AbbVie’s psychiatry expertise and Gilgamesh’s innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders….
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
Recursion recently announced the completion of BioHive-2, Recursion’s new NVIDIA DGX SuperPOD AI supercomputer, powered by 63 DGX H100 systems with a total of 504 NVIDIA…
AC Immune & Takeda Sign Exclusive Option & License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Takeda to receive exclusive option to license global rights to ACI-24.060, a potential first-in-class active immunotherapy designed to delay or slow Alzheimer’s disease progression….
Lycia Therapeutics Completes $106.6 Million Series C Financing to Advance Pipeline of LYTAC Extracellular Protein Degraders to the Clinic
Lycia will use proceeds from financing to progress its lead programs into the clinic for autoimmune and inflammatory diseases….
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
IMUNON, Inc. recently announced DM Clinical Research in Philadelphia is the first site activated and ready for patient recruitment for its Phase 1 study with…
Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy & Related Conditions
Beacon Biosignals recently announced a strategic partnership with Longboard Pharmaceuticals, Inc. that combines Longboard’s drug development expertise with Beacon’s neurophysiological platform to develop a better…
Valneva Reports Further Positive Pivotal Phase 3 Data in Adolescents for its Single-Shot Chikungunya Vaccine
Valneva SE recently reported further positive pivotal Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine. Following the initial analysis up to Day…
Data From First Human Study Demonstrate Excellent Performance of Zerion Pharma’s Dispersome Technology
Zerion Pharma A/S recently announced positive results from the first human clinical study of a Dispersome formulation of the drug Ivacaftor, a pharmaceutical used to…
Genespire Presents Positive Preclinical Proof of Concept Data
Genespire recently presented positive preclinical data at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) currently taking place in…
Mediar Advances First-in-Class Fibrosis Portfolio to the Clinic with First Cohort Dosing in Phase 1 trial of MTX-463 & Establishes Clinical Advisory Board
Mediar Therapeutics, Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt fibrosis progression, today announced that, following FDA clearance of its investigational…
Arecor & Medtronic Diabetes Establish Collaboration to Develop Novel Thermostable Insulin for Implantable Pump Delivery
Medtronic to fund Arecor’s development of Arestat-enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination….
5 Prime Sciences Announces Strategic Collaboration With Lilly in Cardio-Metabolic Diseases
5 Prime Sciences recently announced a strategic collaboration with Eli Lilly and Company dedicated to accelerating target discovery and early development in the field of…
Bluejay Therapeutics Secures $182 Million in Series C Financing to Propel Clinical Pipeline
Bluejay Therapeutics recently announced the successful closure of a $182 million Series C financing round. This capital infusion will accelerate the clinical development of BJT-778,…
Attovia Therapeutics Raises $105 Million in Financing
Attovia Therapeutics recently announced the closing of a $105 million oversubscribed Series B financing, bringing the total capital raised by the company since its launch…
Akoya Biosciences & NeraCare Enter Exclusive Agreement to Enable Personalized Therapy Selection for Early Stage Melanoma Patients
Leveraging Akoya’s market-leading PhenoImager HT platform and clinical development expertise with NeraCare’s Immunoprint test and best-in-class clinical data, the partnership will…
Curia & Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest
Curia and Carterra Inc. recently announced their partnership in hosting a high-throughput biologics symposium slated for May 31 at the Residence Inn at Marriott….
Siren Biotechnology & Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
Siren Biotechnology and Catalent Inc. recently entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene….
On the Path to Net Zero: Vetter Achieves New Sustainability Goals in 2023
Alongside its dynamic growth, Vetter announced that it achieved its sustainability goals for 2023. The Contract Development & Manufacturing Organization (CDMO) recently became a member…
ENA Respiratory Receives USPTO Notice of Allowance for Key Patent Covering First-in-Class Antiviral Innate Immunomodulator
ENA Respiratory recently announced it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent application US 18/112091 titled “Novel molecules” covering claims for….
